Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I

This publication has 22 references indexed in Scilit:

• Adeno-associated Virus 9 Mediated FKRP Gene Therapy Restores Functional Glycosylation of α-dystroglycan and Improves Muscle Functions
  Molecular Therapy, 2013
• Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes
  Human Genetics, 2013
• Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies
  Human Molecular Genetics, 2010
• Mutations alter secretion of fukutin-related protein
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
• Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human
  Neuromuscular Disorders, 2007
• Fukutin-related protein mutations that cause congenital muscular dystrophy result in ER-retention of the mutant protein in cultured cells
  Human Molecular Genetics, 2004
• Post-translational disruption of dystroglycan–ligand interactions in congenital muscular dystrophies
  Nature, 2002
• Mutations in the Fukutin-Related Protein Gene (FKRP) Cause a Form of Congenital Muscular Dystrophy with Secondary Laminin α2 Deficiency and Abnormal Glycosylation of α-Dystroglycan
  The American Journal of Human Genetics, 2001
• Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice
  Human Molecular Genetics, 1995
• Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform
  Human Molecular Genetics, 1994